Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| RNA Binding Protein IGF2BP3 Rehabilitates Glycolysis of Vascular Endothelial Cells to Protect the ox-LDL-induced Cellular Injury via Stabilizing LDHA mRNA. | Cell Biochem Biophys | 2025 | 40159306 | PubTator, text mining | PubMed |
| Prediction of Patients With High-Risk Osteosarcoma on the Basis of XGBoost Algorithm Using Transcriptome and Methylation Data From SGH-OS Cohort. | JCO Precis Oncol | 2025 | 40153688 | PubTator, text mining | PubMed |
| HaloPROTAC3 treatment activates the unfolded protein response of the endoplasmic reticulum in nonengineered mammalian cell lines. | Mol Biol Cell | 2025 | 40105918 | PubTator, text mining | PubMed |
| The N6-methyladenosine reader IGF2BP3 promotes bladder cancer progression through enhancing HSP90AB1 expression. | FEBS J | 2025 | 40105114 | PubTator, text mining | PubMed |
| IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an m6A dependent manner. | Int J Biol Sci | 2025 | 40083693 | PubTator, text mining | PubMed |
| The m6A reader IGF2BP3 promotes HCC progression by enhancing MCM10 stability. | Sci Rep | 2025 | 40065065 | PubTator, text mining | PubMed |
| Histone acetylation activated-IGF2BP3 regulates cyclin D1 mRNA stability to drive cell cycle transition and tumor progression of hepatocellular carcinoma. | Int J Biol Macromol | 2025 | 40037458 | PubTator, text mining | PubMed |
| Creation of an innovative diagnostic framework for hepatocellular carcinoma employing bioinformatics techniques focused on senescence-related and pyroptosis-related genes. | Front Oncol | 2025 | 40018411 | PubTator, text mining | PubMed |
| IGF2BP3 prefers to regulate alternative splicing of genes associated with the progression of gastric cancer in AGS cells. | Discov Oncol | 2025 | 39998701 | PubTator, text mining | PubMed |
| IGF2BP3 facilitates the osteogenic differentiation of bone marrow mesenchyml stem cells via upregulating KLK4. | Connect Tissue Res | 2025 | 39988894 | PubTator, text mining | PubMed |
| RBM15 recruits myeloid-derived suppressor cells via the m6A-IGF2BP3/CBR3-AS1/miR-409-3p/CXCL1 axis, facilitating radioresistance in non-small-cell lung cancer. | J Transl Med | 2025 | 39962467 | PubTator, text mining | PubMed |
| Novel combined tumor autoantibody detection in serological diagnosis of gastric cancer. | Int J Clin Exp Pathol | 2025 | 39949595 | PubTator, text mining | PubMed |
| CircPRMT5, a Potential Salivary Biomarker, Facilitates the Progression of Head and Neck Squamous Cell Carcinoma via the IGF2BP3-SERPINE1 Pathway. | Int J Nanomedicine | 2025 | 39931528 | PubTator, text mining | PubMed |
| METTL3-mediated NFAT5 Upregulation Promotes Cervical Cancer Progression Through Enhancing the Mitochondrial Function by Transcriptional Regulation of PRDX1. | J Biochem Mol Toxicol | 2025 | 39925026 | PubTator, text mining | PubMed |
| Nitidine chloride inhibits the progression of hepatocellular carcinoma by suppressing IGF2BP3 and modulates metabolic pathways in an m6A-dependent manner. | Mol Med | 2025 | 39910429 | PubTator, text mining | PubMed |
| Curcumol promotes immune cell invasion and inhibits angiogenesis in colon cancer by decreasing IGF2BP3 expression. | Biochem Biophys Res Commun | 2025 | 39899937 | PubTator, text mining | PubMed |
| Comprehensive analysis of ceRNA Networks in UCEC: Prognostic and therapeutic implications. | PLoS One | 2025 | 39883704 | PubTator, text mining | PubMed |
| IGF2BP3 is upregulated in endometrial cancer and tightly regulates the growth of drug-resistant endometrial cancer cells via HMGA1. | Sci Prog | 2025 | 39878052 | PubTator, text mining | PubMed |
| Disrupting of IGF2BP3-stabilized CLDN11 mRNA by TNF-α increases intestinal permeability in obesity-related severe acute pancreatitis. | Mol Med | 2025 | 39856555 | PubTator, text mining | PubMed |
| Baicalin attenuates the immune escape of oral squamous cell carcinoma by reducing lactate accumulation in tumor microenvironment. | J Adv Res | 2025 | 39814222 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=14